Clinical oncology最新文献

{"title":"OncoFlash - Research Updates in a Flash! (Sep 2025)","authors":"F. Kazmi , C. Crockett","doi":"10.1016/j.clon.2025.103917","DOIUrl":"10.1016/j.clon.2025.103917","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"45 ","pages":"Article 103917"},"PeriodicalIF":3.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paid MBP advert Journals_AI_Conference_280x210_August_Launch_01","authors":"","doi":"10.1016/S0936-6555(25)00160-8","DOIUrl":"10.1016/S0936-6555(25)00160-8","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"44 ","pages":"Article 103905"},"PeriodicalIF":3.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144632423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RCR Meetings","authors":"","doi":"10.1016/j.clon.2025.103906","DOIUrl":"10.1016/j.clon.2025.103906","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"44 ","pages":"Article 103906"},"PeriodicalIF":3.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144632422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility Study of an Efficient Plan Pool Adaptive Radiotherapy Technology Based on Low-dose Computed Tomography for Cervical Cancer","authors":"F. Sun ,&nbsp;Y. Xu ,&nbsp;X. Xu ,&nbsp;W. Gong ,&nbsp;Z. Mo ,&nbsp;L. Jia ,&nbsp;S. Qin ,&nbsp;G. Gan","doi":"10.1016/j.clon.2025.103903","DOIUrl":"10.1016/j.clon.2025.103903","url":null,"abstract":"<div><h3>Background</h3><div>Online adaptive radiotherapy (oART) involves a complex workflow across multiple departments, requiring significant resources and increasing the workload of radiation oncologists (ROs) and physicists. For cervical cancer, there is a need for a low-dose, image-guided adaptive radiotherapy solution that is both efficient and clinically effective</div></div><div><h3>Aims</h3><div>The aim is to explore the feasibility and performance of a plan-pool adaptive radiotherapy (plan-pool ART) workflow, with a focus on efficiency and dosimetric benefits for both the tumour and organs at risk (OARs).</div></div><div><h3>Materials and Methods</h3><div>A plan-pool ART framework was developed for cervical cancer radiotherapy based on the daily low-dose computed tomography (LDCT). The LDCT images were synthesised into high-quality restorative CT (RCT) images by an image-synthesis model. A total of 257 fractionated fan-beam computed tomography (FBCT) datasets from 17 cervical cancer patients treated with the oART regimen were collected (171 fractions treated with oART and 86 fractions treated with the original plan). A support vector machine (SVM) was used to train (180 cases) and evaluate (77 cases) the oART classification model, which predicts whether the fraction needs to execute oART. The oART classification model selects the daily treatment plan that best aligns with the patient's anatomical positions from the plan pool. Finally, the performance of image-guided radiotherapy (IGRT), plan-pool ART, and triggered oART (trigger-oART) techniques was compared by simulating treatments for 5 cervical cancer cases.</div></div><div><h3>Results</h3><div>The oART classification model achieved high predictive performance, with an under the curve (AUC) of 0.98, accuracy of 0.86, recall of 0.89, and specificity of 0.92. Plan-pool ART reduced the number of oART execution (1.4 vs 3.0 for trigger-oART) while optimising dosimetry. Compared to IGRT, plan-pool ART decreased mean bladder dose (3122cGy vs 3258cGy) and rectum dose (3265cGy vs 3325cGy), along with lower V_4500cGy values for both organs. Target coverage remained comparable across techniques, but IGRT showed greater variability in CTV D_99%, leading to potential underdosing.</div></div><div><h3>Conclusion</h3><div>The simulation results demonstrate that the plan-pool ART technology is feasible, ensuring reliable target dose coverage, reducing the dose to OARs, and lowering the number of oART implementation. This approach offers a promising new technical solution for clinical treatment.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"45 ","pages":"Article 103903"},"PeriodicalIF":3.2,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144696535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to ‘Dose Accumulation for Pelvic Stereotactic Ablative Radiotherapy Reirradiation. In Regard to Slevin et al.’","authors":"F. Slevin ,&nbsp;M. Nix ,&nbsp;C. O'Hara ,&nbsp;J. Entwisle ,&nbsp;J. Lilley ,&nbsp;C. Thompson ,&nbsp;M. Tyyger ,&nbsp;A.L. Appelt ,&nbsp;L.J. Murray","doi":"10.1016/j.clon.2025.103901","DOIUrl":"10.1016/j.clon.2025.103901","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"45 ","pages":"Article 103901"},"PeriodicalIF":3.2,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OncoFlash - Research Updates in a Flash!","authors":"J.T. Nicholson ,&nbsp;R. Simões","doi":"10.1016/j.clon.2025.103898","DOIUrl":"10.1016/j.clon.2025.103898","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"44 ","pages":"Article 103898"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144581009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience of 18F-PSMA-1007 Positron Emission Tomography-Computed Tomography Scanning for Initial Staging of High-Risk Nonmetastatic Prostate Cancer: Scan Results and Treatment Decisions","authors":"J. Staffurth ,&nbsp;S. Mukherjee ,&nbsp;P. Fielding ,&nbsp;E. Renninson ,&nbsp;J.I. Rees","doi":"10.1016/j.clon.2025.103900","DOIUrl":"10.1016/j.clon.2025.103900","url":null,"abstract":"<div><h3>Aims</h3><div>Recent literature has shown the higher accuracy of staging prostate-specific membrane antigen positron emission tomography (PSMA-PET) scans over conventional imaging for high-risk localised prostate cancer patients suitable for radical treatment. All-Wales guidelines recommended PSMA-PET scans prior to radical therapy in 2020.</div></div><div><h3>Materials and Methods</h3><div>We have studied the outcome of high-risk prostate cancer patients referred for a staging PSMA-PET CT scan in Cardiff to identify the proportion for nodal or distant metastases, the association between risk factors and PET positivity, how treatment varied by PET result, and the outcome of men undergoing surgery.</div></div><div><h3>Results</h3><div>Two hundred men underwent staging PSMA PET scans, of whom 143 had no evidence or suspicion of nodal or distant metastases on conventional imaging. Of these 143 patients, 102 (71%), 25 (17.5%), and 16 (11.2%) had post-PET staging of TxN0M0 (_PETN0M0), TxN1M0 (_PETN1M0) and TxNxM1 (_PETM1), respectively. The risk of harbouring microscopic nodal or distant metastases was 12%, 38%, and 72% for men with 1, 2, or 3 high-risk factors, respectively. The risk also increased as the extent of each risk factor increased. The nodal false negative rate for the 22 men with _PETN0M0 disease undergoing prostatectomy was 9.1%, despite the median number of nodes identified being only 8. Considering the entire 200-patient cohort, treatment was strongly influenced by PET results: 56% of _PETN0M0 men had radical treatment to the prostate and 37% to prostate + nodes, 87% of _PETN1M0 men had prostate and pelvic nodal radiotherapy with long-course androgen deprivation therapy (ADT) ± androgen receptor pathway inhibitor (ARPI), whereas 95% of men with _PETM1 disease had permanent ADT therapy ± radiotherapy ± ARPI.</div></div><div><h3>Conclusions</h3><div>Our results reflect international literature and strongly support the role of staging PSMA-PET scans prior to radical therapy in all high-risk prostate cancer patients. Extension to unfavourable intermediate-risk should be considered.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"45 ","pages":"Article 103900"},"PeriodicalIF":3.2,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144686161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real World Multi-centre UK Review of Nivolumab Monotherapy in Metastatic Endometrial Cancer With Mismatch Repair Deficiency During COVID-19","authors":"J. McGrane ,&nbsp;L. Eastlake ,&nbsp;D. Hadjiyiannakis ,&nbsp;S. Lalondrelle ,&nbsp;R. Bowen ,&nbsp;S. Trent ,&nbsp;M. Obeid ,&nbsp;E. Hudson ,&nbsp;R. Agarwal ,&nbsp;S. Gandhi ,&nbsp;T. Young ,&nbsp;R. Kristeleit ,&nbsp;R. Mohammed ,&nbsp;M. Rowe ,&nbsp;S. Dubey ,&nbsp;J. Forrest ,&nbsp;L. Seneviratne ,&nbsp;M. Hussain ,&nbsp;G.J. Melendez-Torres","doi":"10.1016/j.clon.2025.103899","DOIUrl":"10.1016/j.clon.2025.103899","url":null,"abstract":"<div><h3>Introduction</h3><div>Immunotherapy checkpoint inhibition has shown improvement in efficacy and survival in patients with mismatch repair deficient (MMRd) advanced endometrial cancer (mEC) compared to chemotherapy. This is combined with chemotherapy in the first-line setting or as monotherapy in later lines of therapy.</div></div><div><h3>Objective</h3><div>To assess the efficacy, survival and toxicity of nivolumab monotherapy in metastatic endometrial cancer (mEC) in both first and later lines of therapy as used in the NICE COVID-19 systemic anti-cancer (SACT) guidelines.</div></div><div><h3>Methods</h3><div>A multi-centre retrospective review of mEC patients with associated MMRd who received nivolumab as per NICE COVID NG161 at 10 NHS cancer centres. Patient demographics, molecular classification and previous treatments were recorded in addition to treatment responses, duration of response, overall survival, progression-free survival and toxicities. Kaplan-Meier curves analyse the survival data.</div></div><div><h3>Results</h3><div>52 patients were identified. Median age was 67 (37–81) years. 87.5% of patients had endometrioid histology and 75% were oestrogen receptor (ER) positive. 10.4% patients were p53 mutated. 33.3% of mEC patients were stage IV at diagnosis.</div><div>30 (62.5%) patients received nivolumab as first-line mEC therapy. 33 (68.8%) patients received nivolumab 4-weekly. Treatment response was clinician-observed in 34 (70.8%) patients, with 7 (14.5%) more having stable disease.</div><div>52%, 45% and 36% of patients were progression-free at 12, 18 and 24months, respectively. 75%, 55% and 47% of patients were alive at 12, 18 and 24 months.</div><div>There was no significant difference between survival or response whether nivolumab was given in the first line or subsequent lines.</div><div>29 (60.4%) patients have discontinued treatment with 23 (44.2%) being due to progressive disease or death. 18 (37.5%) patients developed G1-2 toxicity, and 3 (6.25%) patients discontinued due to G3 toxicity.</div></div><div><h3>Conclusions</h3><div>This retrospective cohort shows that nivolumab monotherapy has good real-world disease control of mEC patients with MMR deficiency. Toxicity rates were low, and checkpoint monotherapy may be a viable option for selected first-line MMRd mEC patients.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"45 ","pages":"Article 103899"},"PeriodicalIF":3.2,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Clinical Decision-Making in Radiotherapy: A Comparative Analysis of Linear-Quadratic LQ and Linear-Quadratic-Linear LQL Dose Models","authors":"C. Voyant ,&nbsp;D. Julian ,&nbsp;S. Muraro ,&nbsp;V. Bodez ,&nbsp;M. Pinpin ,&nbsp;D. Leschi ,&nbsp;R. Oozeer ,&nbsp;G. Wided ,&nbsp;M.-A. Acquaviva ,&nbsp;S. Prapant ,&nbsp;O. Gahbiche ,&nbsp;N. Bouaouina","doi":"10.1016/j.clon.2025.103893","DOIUrl":"10.1016/j.clon.2025.103893","url":null,"abstract":"<div><h3>Aims</h3><div>Radiotherapy is an essential component of cancer treatment, requiring accurate dose planning to optimise tumour control while sparing healthy tissues. This study, originating from a radiobiology workshop held during the <em>27</em>th <em>Congrès National de Cancérologie et de Radiothérapie-2024</em> in Sousse, Tunisia, aims to investigate advanced dose modelling approaches, focussing on the linear-quadratic (LQ) and linear-quadratic-linear (LQL) models, to refine the calculation of biologically effective doses (BED) and improve treatment personalisation.</div></div><div><h3>Methods</h3><div>The workshop brought together experts in the field to discuss and evaluate the latest advancements in dose modelling, providing a comprehensive overview of current best practices and emerging trends. Using tools such as LQL-equiv and other BED calculators, we integrated patient-specific data (eg, fractionation schedules and organ-at-risk (OAR) constraints) to predict outcomes such as normal tissue complication probabilities (NTCPs). Unlike many theoretical studies, our approach embeds these models within a unified interface tailored to real clinical scenarios, enabling practitioners to simulate and adjust treatment plans based on complex, practical constraints.</div></div><div><h3>Results</h3><div>Through a series of clinical case studies (including treatment interruptions, palliative boosts, and re-irradiation scenarios), participant responses were analysed using the Jaccard similarity index, revealing a significant lack of consensus in treatment planning decisions (mean agreement of 25.83%). This variation illustrates the current ambiguity among clinicians regarding which model to use and how to apply it, despite access to advanced tools. This heterogeneity in decision-making could lead to divergent treatment recommendations for patients with clinically similar profiles.</div></div><div><h3>Conclusion</h3><div>While the LQ and LQL models offer promising tools for personalised radiotherapy, their interpretation and implementation remain highly variable. In addition, the question of professional responsibility in dose equivalence calculations emerged as a key issue as many departments lack clearly defined accountability frameworks. This study emphasises the need for standardised guidelines, enhanced training programs, and decision support systems to reduce interobserver variability and ensure effective clinical adoption, ultimately improving patient care. The findings underscore the importance of harmonising predictive modelling practices to achieve more consistent and effective radiotherapy outcomes.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"45 ","pages":"Article 103893"},"PeriodicalIF":3.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NeoAdjuvant and Adjuvant Strategies With Conformal Radiotherapy and Surgery in Non-small Cell Lung Cancer With Actionable Mutations.","authors":"T Wu, Z Lu, J Chen","doi":"10.1016/j.clon.2025.103891","DOIUrl":"https://doi.org/10.1016/j.clon.2025.103891","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":" ","pages":"103891"},"PeriodicalIF":3.2,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}